MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Rapamycin-Eluting Coronary Stent for PCI: The TARGET IV Trial
A review of the TARGET IV trial evaluating the Firehawk rapamycin-eluting cobalt chromium coronary stent system. Can this new stent increase healing time, reduce adverse events, and eliminate the need for prolonged dual antiplatelet therapy?
By Christiana O. Oshotse, BA, and Robert W. Yeh, MD, MSc, MBA
DAPT Study Compares 12- and 30-Month Treatment in Patients With and Without MI
March 15, 2015—Robert W. Yeh, MD, et al have published findings from the DAPT study online ahead of print in the Journal of the American College of Cardiology simultaneously with the presentation of the study at the American College of Cardiology’s 64th annual scientific session in San Diego, California.
Five-Year Data Published From Medtronic's RESOLUTE Global Clinical Trial Program
February 9, 2017—Five-year safety and efficacy data from the RESOLUTE Global clinical trial program were published online by Robert W. Yeh, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. The investigators evaluated the 5-year cumulative incidence of cardiovascular events after implantation of the Resolute zotarolimus-eluting stent (ZES; Medtronic).
Boston Scientific Initiates Trial of Agent DCB for Coronary In-Stent Restenosis
May 11, 2021—Boston Scientific Corporation announced it has initiated the AGENT investigational device exemption (IDE) trial, which will evaluate the safety and effectiveness of the company’s Agent drug-coated balloon (DCB) in patients with coronary in-stent restenosis (ISR).
Boston Scientific’s Agent Drug-Coated Balloon Receives FDA Approval
March 1, 2024—Boston Scientific Corporation announced it has received FDA approval for the Agent paclitaxel drug-coated balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
Boston Scientific’s Agent DCB Compared to Uncoated Balloon Angioplasty in the AGENT IDE Trial
October 25, 2023—Boston Scientific Corporation announced 12-month results from the pivotal AGENT investigational device exemption (IDE) clinical trial of the company’s Agent drug-coated balloon (DCB).
Study Suggests ACC’s NCDR Registry Data Could Support Clinical Trials
June 21, 2021—The American College of Cardiology (ACC) announced the publication of a study showing that data captured in ACC's National Cardiovascular Data Registry (NCDR) suite of cardiovascular data registries are similar in quality, depth, and granularity when compared to data captured through clinical trials.
Modern Clinical Trials Spotlight
By Ori Ben-Yehuda, MD
Study Examines In-Hospital and Long-Term Outcomes of CTO PCI and High-Risk Non-CTO PCI
May 16, 2023—Using the American College of Cardiology National Cardiovascular Data Registry (NCDR) CathPCI Registry to compare patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) and non-CTO PCI, Almarzooq and colleagues found lower procedural success rates and higher adverse events during index hospitalization in the CTO PCI group, driven mainly by periprocedural myocardial infarction (MI) based on biomarker assessment, bleeding within 72 hours of the procedure, and intraprocedural and postprocedural cardiogenic shock.
Do the New DAPT Guidelines Result in Any Real Changes in Practice?
With John A. Bittl, MD; Robert Yeh, MD, MSc, MBA; Eric A. Secemsky, MD, MSc; Eric R. Bates, MD; and Issam D. Moussa, MD, FACC, FAHA, FSCAI
Hemodynamic Support for High-Risk PCI
Patient selection and procedural strategy are key in treating this evolving patient population.
By Kathleen E. Kearney, MD; James M. McCabe, MD; and Robert F. Riley, MD, MS
